Clinical Study

Nrg Lu-005: A Phase II/III Randomized Study Of Chemoradiation Versus Chemoradiation Plus Atezolizumab Immunotherapy In Limited Stage Small Cell Lung Cancer (Ls-Sclc)

Posted Date: Feb 5, 2020

  • Investigator: Emily Daugherty
  • Specialties: Cancer, Lung Cancer, Oncology, Pulmonary Diseases, Radiation Oncology
  • Type of Study: Drug

The purpose of this study is to compare progression free survival (PFS) and overall survival for patients with limited stage small cell lung cancer (LS-SCLC) treated with chemoradiation +/- atezolizumab.


Patients Over Age 18 Who Have A Proven Diagnosis Of Limited Stage Small Cell Lung Cancer, Ecog 0-2 Who Have No Prior Malignancy Within 2 Past Two Years And No Prior Radiation To Chest


Immunotherapy, Small Cell Lung Cancer, Radiation Therapy

For More Information:

Dr. Emily Daugherty, Md

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.